Amarillo Biosciences, Inc. (AMAR.OB) reports that Dr. Joseph Cummins, President & CEO, will be featured on Market News First (www.mn1.com).
The exclusive interview with the MN1 news team is scheduled for 12:15 PM EDT on June 22. Dr. Cummins will be reviewing information about the Company’s last two news releases on June 15 and June 21. These news releases reported on an upcoming clinical trial on chronic cough and additional new clinical sites for the on-going Phase 2 study in HIV+ patients
Amarillo Biosciences, Inc. is a Company Covered by Dutton Associates.
Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 12% of Amarillo Biosciences shares and has provided over $17.9 million in loans, grants and equity investments.
The Company’s primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren’s syndrome, Behcet’s disease, and opportunistic infections in patients who are HIV positive.
In its 23-year history, ABI has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon.
Let us hear your thoughts below: